Biotech Backers Learn To Live With Exit-By-Earn-Out
This article was originally published in The Pink Sheet Daily
Executive Summary
Even as both public investors and pharma companies more vigorously sniff out biopharma opportunities, exits for venture-backed firms remain scarce. Can risk-sharing acquisitions save the day?
You may also be interested in...
Clovis Oncology Seeks $149.5 Million IPO
The Colorado cancer drug maker is seeking financing through the public capital markets.
Clovis Oncology Seeks $149.5 Million IPO
The Colorado cancer drug maker is seeking financing through the public capital markets.
Emergent BioSolutions Takes Out Troubled Trubion For $97 Million
Known for its biodefense work, Emergent used cash from its anthrax vaccine contracts to scoop up a developer of antibody-like therapies for autoimmune and cancer indications.